Retatrutide and Energy Expenditure: Burning More at Rest

The weight loss equation has two sides: energy in and energy out. Every GLP-1 medication before retatrutide focused almost exclusively on the "energy in" side through appetite suppression. This works -- semaglutide produces 15-17% weight loss by reducing food intake. But it leaves the "energy out" side untouched, allowing metabolic adaptation to gradually erode results. Retatrutide's glucagon receptor activation changes this by directly increasing energy expenditure, attacking obesity from both sides simultaneously (Jastreboff et al., NEJM 2023).

Components of Daily Energy Expenditure

Your body burns calories through four primary pathways, and retatrutide affects at least two of them:

The critical insight: glucagon receptor activation increases BMR, which represents 60-70% of total daily energy expenditure. Even a 5-10% increase in BMR translates to a meaningful increase in total daily calorie burn. This is the mechanism most likely responsible for retatrutide's additional weight loss beyond tirzepatide.

How Glucagon Increases Energy Expenditure

Hepatic Fat Oxidation

The liver is one of the most metabolically active organs. Glucagon receptor activation upregulates hepatic fat oxidation pathways, forcing the liver to break down more fatty acids for energy. This process generates heat as a byproduct, contributing to overall thermogenesis. The liver essentially becomes a more active metabolic furnace.

Brown Adipose Tissue Activation

Brown fat is specialized adipose tissue that burns calories to generate heat rather than storing them. Glucagon activates brown fat through UCP1 (uncoupling protein 1) upregulation, turning stored energy into heat. While adults have limited brown fat compared to infants, the amount present is metabolically significant when activated.

Futile Cycling

Glucagon promotes metabolic pathways that consume energy without producing useful work -- a phenomenon called "futile cycling." Simultaneously activating opposing metabolic pathways (such as glycogen synthesis and breakdown) wastes energy as heat. While inefficient from a survival perspective, this is precisely what you want during weight loss.

Clinical Evidence for Increased Expenditure

While direct calorimetry data from retatrutide trials is limited, several indirect observations support increased energy expenditure:

• Additional weight loss beyond appetite suppression: Retatrutide produces more weight loss than tirzepatide despite similar appetite suppression levels, suggesting an additional energy expenditure component
• Dramatic liver fat reduction: The 80%+ liver fat reduction seen in some participants is consistent with aggressive hepatic fat oxidation, which generates energy expenditure
• Body composition data: The favorable fat-to-lean mass ratio (75-80% fat loss) suggests increased fat-specific energy utilization
• Glucagon receptor pharmacology: Decades of research confirm glucagon's thermogenic properties in controlled studies

Practical Implications

The energy expenditure increase from retatrutide has several practical implications for patients:

• Metabolic adaptation protection: The glucagon-driven calorie burn partially offsets the metabolic slowdown that occurs during weight loss, potentially reducing the severity of weight loss plateaus
• More sustainable weight loss: Dual-mechanism weight loss (eating less AND burning more) may produce more durable results than appetite suppression alone
• Possible warmth sensation: Some patients may notice feeling warmer, which reflects thermogenic activity
• Hydration needs: Increased metabolic activity may increase fluid needs. Stay well-hydrated throughout treatment

To explore currently available weight loss treatments, visit our treatments page.